Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici, which accelerates EUR550,000 in milestone payments to coincide with CTA approval. This enables OncoZenge to shift its planned phase III study to a fully European setup, aligning more closely with its regulatory and commercial focus. We view the move as a strategic refinement that could strengthen trial execution and reflects the growing confidence and alignment between OncoZenge and Molteni.
LÄS MER
